Bio-Optronics Renews Its Global Impact Partnership with the Society for Clinical Research Sites
The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced the renewal of a two-year relationship with Bio-Optronics, a leading healthcare information technology company, focusing specifically on workflow optimization. Bio-Optronics will participate as a Global Impact Partner (GIP) and align with 30 other sponsors, CROs, and service providers dedicated to promoting high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally.
Christine Pierre, president of SCRS, said, “We are thrilled to have Bio-Optronics continue to show their support of the sites through their collaboration with SCRS as a Global Impact Partner. We welcome the opportunity for further collaboration between the two organizations.”
“SCRS continues to serve as a the most prominent resource for the research site community to thrive and collectively grow, and we are eager to continue this partnership, serve as a resource to the site community and continue to grow Clinical Conductor CTMS to further accommodate the needs of research sites,” stated Maria Durkin, Chief Business Officer of Bio-Optronics.
As a Global Impact Partner (GIP), Bio-Optronics will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
